Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...
The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...
InvestorsHub on MSN
HCW Biologics highlights positive findings for CAR-T therapy manufacturing
HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 ...
HaemaLogiX earlier this week announced it has received TGA approval to commence a Phase 1 clinical trial of its KMCAR™ CAR-T cell therapy targeting multiple myeloma, marking a key milestone for the ...
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
Professor Gordon Cook says careful patient selection is needed with CAR-T cell therapy, noting its potential in a disease ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work. What major challenge of traditional CAR-T does the in vivo alleviate/address? In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results